Publications

46. Chipps, B.E. Letter to the Editor, Systemic Reaction to Omalizumab. Ann Allergy Asthma Immunol. 2006;97:267. View

45. Chipps, B.E., Spahn, J.D., Sorkness, C.A., Baitnger, L., Sutton, L.B., Emmett, A.H., Dorinsky, P.M. Variability in Asthma Severity in Pediatric Subjects with Asthma Previously Receiving Short-Acting B2-Agonists. J Pediatr. 2006;148:517-21. View

44. Sander, N., Fusco-Walker, S.J., McElvain, J., Chipps, B.E. Running on Empty: The Need for Dose counters on Pressurized Metered-Dose Inhalers. Ann Allergy Asthma Immunol. 2006;97:34-38. View

43. Spahn, J.D., Chipps, B.E., Office-based objective measures of lung function in childhood asthma. J Pediatr, 2006; 148: 11-15. View

42. Chipps, B.E., Haselkorn, T., Lee, J.H., Miller,
D.P., Wenzel, S.E., Gender Differences in IgE-Mediated Allergic
Asthma in the Epidemiology and Natural History of Asthma: Outcomes
and Treatment Regimens (TENOR) Study. Journal of Asthma, 2006; 43:179-184. View

41. Borish, L. Chipps, B.E., Deniz, Y., Zheng, B., Dolan, C., Total Serum IgE levels in a large cohort of subjects with severe or difficult to treat asthma. Ann Allergy Asthma Immunol.
2005;95:247-253 View

40. Chipps, B.E., Murphy, K.M., Assessment and Treatment of Acute Asthma in Children. J Pediatr 2005; 147:288-94. View

39. Chipps, B.E., Determinants of asthma and its clinical course. Ann Allergy Asthma Immunol. 2004;93:309-316 View

38. Chipps, B.E., Marshik, P.L., Targeted IgE Therapy for Patients With Moderate to Severe Asthma. Biotechnology Healthcare -July/August 2004;56-61. View

***Updated 1/13/2021***

FROM CAPITAL ALLERGY & RESPIRATORY DISEASE CENTER

COVID Vaccine Update

Click Here to learn more

We do not expect to be a site for administration of the COVID19 vaccine.  Please check with your local public health department.

Use this link for more information on the state of California’s tiered system for vaccine administration.

https://covid19.ca.gov/vaccines/#When-can-I-get-vaccinated

************************************************

Due to current recommendations made by the US Government/CDC – The Following will go into effect until further notice.

Within the health care community as a whole, there has been an overall increase in the number of patients not seeking necessary medical treatment due to concerns about COVID-19.

If you have a medical problem, please contact your health care provider. It’s important not to delay seeking treatment when you need it.

We are currently open for in-office visits and will continue to offer telemedicine visits moving forward. We understand you might have concerns about coming in to see your health care provider. We want you to know about the steps we are taking to ensure your safety and help prevent the spread of infection:

o Mandatory Masking – All patients and visitors must be masked while in any of our care sites. Please wear a mask or face covering when you enter our facility.

o Limiting Individuals at Appointments – We will limit who is present at a patient visit. Only the patient will be allowed into the facility. If the patient is a minor, only one parent/guardian will be allowed to accompany the patient.

o Temperature Checks – All patients (and parent/guardian if patient is a minor) will have their temperatures checked at the door. Anyone with a temperature of 100 degrees or higher will be asked to reschedule their appointment or conduct the appointment via telemedicine.

o Employee Screening – We’ve instituted mandatory employee temperature screenings before each shift.

New Injection Hours – Effective 7/6/2020

Folsom Office
Monday 8:00-11:45 / 1-4:45
Tuesday Closed
Wednesday 8:00-11:45 / 1-4:45
Thursday 8:00-11:45 / 1-4:45
Friday 8:00-11:45 / 1-4:45

Roseville Office
Monday 9:00-11:45 / 1-4:45
Tuesday 8:00-11:45 / 1-4:45
Wednesday 8:00-11:45 / 1-4:45
Thursday 8:00-11:45 / 1-5:45
Friday 8:00-11:45 / 1-4:45

Sacramento
Monday 9:00-4:45
Tuesday 8:00-5:45
Wednesday 8:00-4:45
Thursday 9:00-4:45
Friday 8:00-4:45